INVENTING A NEW
ROADMAP FOR BIOTECH

Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite? technologies, such as VelocImmune? which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

FOR 30 YEARS, OUR
MISSION HAS BEEN TO
USE THE POWER OF
SCIENCE TO BRING
NEW MEDICINES TO
PATIENTS... OVER
AND OVER AGAIN.

Neil Stahl, PhD, Executive VP,
Research and Development

2018 annual report PDF download

Check out our 2018 annual materials. The Responsibility Report and Annual Report are now online.

Read our annual report
and responsibility report

2018 responsibility report PDF download

REGENERON BY THE NUMBERS

  • 30
    years of scientific
    leadership
  • 7,300+
    employees
    worldwide
  • 700+
    employees with
    an MD, PhD or
    PharmD degree
  • 6TH
    consecutive year
    in Forbes' World's
    Most Innovative
    Companies
  • #1
    ranking in Science
    magazine’s global Top
    Employer survey for six
    of the past eight years
  • 31,000+
    employee volunteer hours
    for 100+ organizations
    in 2018
  • 7
    FDA-approved
    medicines
  • 94%
    of our waste
    diverted from
    landfill, reaching
    our goal
  • 100%
    of drug candidates
    invented and
    developed in-house
  • 500,000+
    exomes sequenced
    to date
  • 100+
    publications in 2018
  • 20
    product candidates in
    clinical development
    across multiple
    therapeutic areas
  • Shingo Institute: The Shingo Prize, 2019

    Great Places to Work: Best Workplace in Ireland, 2019

    Science: #1 Top Employer, 2018

    Forbes: Top 10 Most Innovative Companies, 2018

    Civic 50: Most Community-Minded Companies in the Nation, 2018

    Fortune: Best Companies to Work for, 2018

  • MIT Technology Review: Top 10 Smartest Companies, 2017

    Fortune: Future 50, 2017

    Barron’s: World’s Best CEOs, 2016

    Scrip Award: R&D Team of the Year, 2016

    Crain’s New York Business: Fast 50, 2015

LEADERSHIP

We are the only biopharmaceutical company to be led by physician-scientists for more than 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

Our leadership

A FOCUS
ON SCIENCE

From our first days, science has remained our central guiding principle.

Our journey

咪咪网